Minipuberty of Infancy and the Timing of Pubertal Development in Adolescence: a Follow-up of the Infant Feeding and Early Development (IFED) Cohort
Study Details
Study Description
Brief Summary
Background:
Earlier puberty is associated with adverse health throughout a person s life. The average age when puberty begins has been declining over the past decades in girls, and may also be declining in boys. The reasons for this shift are unknown.
Objective:
To determine whether internal (physical, hormonal) or external (feeding, environment) factors during infancy affect growth and the timing of puberty.
Eligibility:
Mothers (or other parent/guardian) and their children who completed the Infant Feeding and Early Development (IFED) study.
Design:
Participants will complete all activities at home.
Participant mothers will fill out two 15-minute questionnaires:
-
One will be about themselves. They will answer questions about their body size in childhood, their puberty, and their pregnancies.
-
The other will be about their child. They will answer questions about their child s puberty and lifestyle.
Child participants will fill out a questionnaire about their body changes during puberty. This will take 10 minutes.
Participants will be sent an electronic scale and a measuring tape. They will measure the child s weight, height, and waist and hip circumference. These numbers can be submitted online or by phone or mail.
Participants will receive a kit for collecting urine samples. Child participants will collect urine in a cup upon waking 4 days in a row. A special filter card is dipped in the cup then hung to dry. The dried cards will be mailed back.
Participants will allow researchers to access their child s medical records.
Questionnaires and body measurements will be repeated after 6 and 12 months. Urine sample collection will be repeated after 12 months.
All questionnaires can be done either online, by mail, or by phone on request.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Study Description: Our overarching hypothesis is that endogenous and exogenous factors related to hypothalamic-pituitary-gonadal (HPG) axis activity during minipuberty of infancy are associated with childhood growth, the timing of pubertal development, and HPG axis activity in adolescence. To examine this hypothesis, we will conduct an observational follow-up study of children previously enrolled as infants in the Infant Feeding and Early Development (IFED) cohort. This follow-up study will be conducted remotely with data collection via email/online, mail and telephone by contractors at Social & Scientific Systems (SSS), a DLH Holdings Company, working on behalf of NIEHS.
Objectives: Primary Objective: To assess whether endogenous (e.g. hormone concentrations and size of hormone-sensitive organs) and exogenous (e.g. infant feeding method, exposure to endocrine disrupting chemicals) factors during minipuberty of infancy are related to a) growth, b) timing of pubertal development, and c) HPG axis activity in adolescence.
Endpoints: Primary Endpoints: a) Height, weight and body mass index (BMI) b) Onset of breast, pubic hair and/or genital development c) Urinary metabolites of reproductive hormones (e.g. gonadotropins and sex steroids)
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| IFED-2 Children who participated in the IFED study as infants (2010-2014) and a parent/guardian will be enrolled in this follow-up study in childhood and followed for at least one year. |
Outcome Measures
Primary Outcome Measures
- To assess whether growth, timing of pubertal development, and hypothalamic-pituitary-gonadal (HPG) axis activity in childhood and adolescence are related to endogenous and exogenous endocrine-related factors during minipuberty of infancy. [Various time points in childhood/adolescence (study enrollment, 6-month and 12-month follow-up visits currently planned). We anticipate that children will be 8-12 years of age at enrollment (2022) and followed prospectively.]
1)Growth in height, weight and body mass index 2)Onset of pubic hair development, breast development (females), genital development (males) 3)Urinary concentrations of reproductive hormone metabolites (e.g., gonadotropins, estradiol, testosterone)
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Completion of the original IFED study, defined as participants who did not withdraw from the study or were not withdrawn by the investigator prior to the end of original follow-up (up to 7 months in males and 9 months in females) and who provided at least the minimum number of blood samples (3 for boys, 4 for girls) across the original study period (N=283 eligible families).
-
Ability of subject and mother to understand and the willingness to review informed assent and consent documents, respectively, and indicate agreement to participate.
EXCLUSION CRITERIA:
We will not exclude any participants that meet the inclusion criteria from participating in the study overall or in any of the study procedures. We will collect information, via maternal report and linked medical records, on relevant medical diagnoses and the use of medications that may affect hormone levels, growth, and pubertal development. We may exclude participants with reported conditions or medication use (listed below) from analyses of some study aims or in sensitivity analyses.
Diagnoses/conditions:
-
Central or peripheral precocious puberty
-
Delayed puberty
-
Growth hormone deficiency
-
Stunted or delayed growth
-
Idiopathic short stature
-
Hypopituitarism
-
Thyroid conditions, such as hyperthyroid, hypothyroid, Graves disease, Hashimoto s thyroiditis
-
Genetic conditions, such as Prader-Willi syndrome, Turner syndrome, and Noonan syndrome
Medications:
-
Gonadotropin-Releasing Hormone Agonists (e.g., leuprolide acetate (Lupron Depot), triptorelin (Triptodur), histrelin implant (Supprelin LA))
-
Hormone therapy (e.g., testosterone, estrogen)
-
Synthetic human growth hormone or IGF-1
-
Synthetic thyroid hormone (e.g., levothyroxine)
-
Anti-thyroid medications (e.g., methimazole, propylthiouracil) or radioactive iodine treatment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institute of Environmental Health Sciences (NIEHS) | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Institute of Environmental Health Sciences (NIEHS)
Investigators
- Principal Investigator: Dale Sandler, Ph.D., National Institute of Environmental Health Sciences (NIEHS)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10000945
- 000945-E